Investigation of the mechanism underlying the antihypertensive effect of catheter-based radiofrequency renal sympathetic denervation in hypertensive dogs
- Authors:
- Fenglin Jiang
- Hui Li
- Fuying Zhu
- Lixiong Zeng
- Xiaoyan Wang
- Xinguo Wang
- Zhijie Shen
- Kan Yang
- Zhihui Zhang
View Affiliations
Affiliations: Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China
- Published online on: December 22, 2014 https://doi.org/10.3892/br.2014.410
-
Pages:
254-260
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The present study aimed to assess the antihypertensive efficacy and safety of catheter‑based radiofrequency renal sympathetic denervation (RSD) in hypertensive dogs. Furthermore, the study investigated the possible antihypertensive mechanism of radiofrequency RSD through measuring the postoperative serum concentrations of angiotensin II (AngII), nicotinamide adenine dinucleotide phosphate oxidase (NADPH‑ox), malondialdehyde (MDA), nitric oxide (NO) and endothelial NO synthase (eNOS). A total of 12 beagles were randomly divided into the surgery (n=6) and the sham‑surgery groups (n=6). The hypertension model was established using a high‑fat diet. The surgery group received catheter‑based radiofrequency RSD, while the sham‑surgery group only received renal arteriography. Blood pressure was measured prior to the surgery and 3 days, 1 and 2 weeks, and 1, 2 and 3 months after the surgery. The serum concentrations of AngII, NADPH‑ox, MDA, NO and eNOS were measured prior to the surgery and 1 week, and 1 and 3 months after the surgery. Following the establishment of the model, the systolic arterial pressure (SAP), diastolic arterial pressure (DAP) and mean arterial pressure (MAP) of the surgery and the sham‑surgery groups were all significantly increased above the baseline (P<0.05), but there was no significant difference between the two groups. SAP, DAP and MAP in the surgery group at 1 and 3 months after the surgery were significantly decreased compared to the levels measured prior to the surgery and those in the sham‑surgery group (P<0.05). Three months after the surgery, the serum creatinine level was normal and renal arteriography did not show renal artery stenosis. Compared to those measured prior to the surgery, the concentrations of serum AngII, NADPH‑ox and MDA in the surgery group at 1 week, and 1 and 3 months after the surgery were decreased, while the concentrations of serum NO and eNOS were increased (P<0.05). The above indicators measured at the same time points demonstrated statistically significant differences between the surgery and the sham‑surgery groups (P<0.05). In conclusion, catheter‑based radiofrequency RSD may inhibit the renin‑angiotensin system and the oxidative stress response, as well as improve vascular endothelial function, thus significantly reducing blood pressure through the reduction of sympathetic activity in hypertensive dogs.
View References
1
|
Krum H, Schlaich M, Whitbourn R, et al:
Catheter-based renal sympathetic denervation for resistant
hypertension: a multicentre safety and proof-of-principle cohort
study. Lancet. 373:1275–1281. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Krum H, Schlaich MP, Sobotka PA, et al:
Percutaneous renal denervation in patients with treatment-resistant
hypertension: final 3-year report of the Symplicity HTN-1 study.
Lancet. 383:622–629. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Papademetriou V, Doumas M and Tsioufis K:
Renal sympathetic denervation for the treatment of
difficult-to-control or resistant hypertension. Int J Hypertens.
2011:1965182011.PubMed/NCBI
|
4
|
Lohmeier TE, Iliescu R, Liu B, et al:
Systemic and renal-specific sympathoinhibition in obesity
hypertension. Hypertension. 59:331–338. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Symplicity HTN-1 Investigators, .
Catheter-based renal sympathetic denervation for resistant
hypertension: durability of blood pressure reduction out to 24
months. Hypertension. 57:911–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Symplicity HTN-2 Investigators, . Esler
MD, Krum H, et al: Renal sympathetic denervation in patients with
treatment-resistant hypertension (The Symplicity HTN-2 Trial): a
randomised controlled trial. Lancet. 376:1903–1909. 2010.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Allen TR: Current status of lumbar
sympathectomy. Am Surg. 42:89–91. 1976.PubMed/NCBI
|
8
|
Babior BM: NADPH oxidase: an update.
Blood. 93:1464–1476. 1999.PubMed/NCBI
|
9
|
Maboudou P, Mathieu D, Bachelet H, et al:
Detection of oxidative stress. Interest of GC-MS for
malondialdehyde and formaldehyde monitoring. Biomed Chromatogr.
16:199–202. 2002. View
Article : Google Scholar : PubMed/NCBI
|
10
|
Carlson SH and Wyss JM: Neurohormonal
regulation of the sympathetic nervous system: new insights into
central mechanisms of action. Curr Hypertens Rep. 10:233–240. 2008.
View Article : Google Scholar : PubMed/NCBI
|
11
|
DiBona GF and Kopp UC: Neural control of
renal function. Physiol Rev. 77:75–197. 1997.PubMed/NCBI
|
12
|
Rafiq K, Noma T, Fujisawa Y, et al: Renal
sympathetic denervation suppresses de novo podocyte injury and
albuminuria in rats with aortic regurgitation. Circulation.
125:1402–1413. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Beevers G, Lip GY and O'Brien E: ABC of
hypertension: the pathophysiology of hypertension. BMJ.
322:912–916. 2001. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kayhan FE, Koldemir M, Cagatay P, et al:
Prevalence of endothelial nitric oxide synthase E298D polymorphism
in Turkish patients with essential hypertension. Diabetes Metab
Syndr. 7:12–16. 2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Rees DD, Palmer RM and Moncada S: Role of
endothelium-derived nitric oxide in the regulation of blood
pressure. Proc Natl Acad Sci USA. 86:3375–3378. 1989. View Article : Google Scholar : PubMed/NCBI
|